Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05254990 · ClinicalTrials.gov registry record · Phase 3
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
A Phase 3 study, sponsored by Dompé Farmaceutici S.p.A.
- Terminated
- Registry status
- Phase 3
- Development phase
- 414
- Enrollment target
NCT05254990 is a Phase 3 study that was terminated before completion, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 414 participants.
The verdict
NCT05254990, a Phase 3 study, was terminated before completion, sponsored by Dompé Farmaceutici S.p.A.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 414 participants
- Enrollment target
Study Summary
Primary objective: \- To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28. Key secondary objectives: * To compare the efficacy of reparixin vs placebo in all-cause mortality at day 180. * To compare the efficacy of reparixin vs placebo in proportion of patients alive and discharged at day 28 * To compare the efficacy of reparixin vs placebo in ventilatory-free days at day 28. * To compare the efficacy of reparixin vs placebo in proportion of patients with IMV (or ECMO) by day 28. * To compare the efficacy of reparixin vs placebo in length of primary hospital stay. Other efficacy objectives \- To compare the efficacy of reparixin vs placebo on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: \- To evaluate safety and tolerability of oral reparixin versus placebo in the specific clinical setting.
Interventions
- OTHER Placebo
- DRUG Reparixin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2024-09-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05254990
The ClinicalTrials.gov registry entry for NCT05254990 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05254990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05254990 about?
NCT05254990 is a clinical study titled "Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia". Primary objective: \- To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28. Key secondary objectives: * To compare the efficacy of reparixin vs placebo in all-cause mortality at day 180. * To compare the efficacy of reparixin vs ...
What is the current status of trial NCT05254990?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 414 participants. The study started on 2022-04-27. Estimated completion is 2024-09-27.
What interventions are being tested in trial NCT05254990?
The interventions under investigation include: Placebo (OTHER), Reparixin (DRUG).
Who is sponsoring clinical trial NCT05254990?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.